Discontinuation (procedure)

Biogen Shuffles Staff and Exits AAV Gene Therapy Programs After Strategic Shift

2 weeks ago talkbio0Tagged AAVS1 gene, Biogen, Biotech Layoffs, Discontinuation (procedure), gene therapy, layoffs, Pharma, staff reorganization

Biogen; AAV gene therapy; layoffs; staff reorganization; biotech layoffs; pharma restructuring; gene therapy discontinuation

Amylyx Discontinues Rare Disease Program After Relyvrio Fails to Show Benefit Over Placebo

2 months ago talkbio0Tagged AMX0035, Amylyx, Amyotrophic Lateral Sclerosis, Clinical trial failure, Discontinuation (procedure), disease program, Infrequent, Placebos, Progressive, Relyvrio, Supranuclear paralysis

Amylyx; Relyvrio; AMX0035; progressive supranuclear palsy; ALS; clinical trial failure; rare disease program; placebo; discontinuation

Response Pharma: RDX-002 Limits Weight Regain After GLP-1 Therapy – Positive Phase II Results Announced

2 months ago talkbio0Tagged cardiometabolic health, Discontinuation (procedure), Glucagon-Like Peptide 1, iMTP, Inhibitor, Obesity, Phase 2 Clinical Trials, postprandial, RDX-002, Response process, Triglycerides, weight regain

Response Pharmaceuticals; RDX-002; GLP-1 discontinuation; weight regain; obesity; Phase II clinical trial; postprandial triglycerides; cardiometabolic health; iMTP inhibitor

AstraZenecas Truqap Posts Another Pivotal Disappointment as Phase III Prostate Cancer Study Fails

5 months ago talkbio0Tagged ADT, androgen-deprivation therapy, AstraZeneca, CAPItello-280, capivasertib, Clinical Trials, Discontinuation (procedure), docetaxel, Failure (biologic function), Inhibitor, Metastatic castration-resistant prostate cancer, oncology setback, Phase 3 Clinical Trials, Progression-Free Survival, Proto-Oncogene Proteins c-akt, Radiographic, Survival, Truqap

Truqap, capivasertib, AstraZeneca, Phase III trial failure, CAPItello-280, metastatic castration-resistant prostate cancer (mCRPC), AKT inhibitor, docetaxel, androgen-deprivation therapy (ADT), oncology setback, clinical trial discontinuation, radiographic progression-free survival, overall survival

Cassava Sciences Discontinues Alzheimer’s Program After Simufilam Fails Second Phase 3 Trial

7 months ago talkbio0Tagged Alzheimer 's disease, Discontinuation (procedure), Drug Development, Failure (biologic function), Manihot esculenta, Phase 3 trial, Simufilam

Cassava Sciences, simufilam, Alzheimer’s disease, Phase 3 trial failure, drug development discontinuation

Lava cuts jobs by 30% after key drug discontinued

8 months ago talkbio0Tagged cash runway, Discontinuation (procedure), LAVA, LAVA-1266, mCRPC, restructuring, strategic alternatives

LAVA Therapeutics, restructuring, workforce reduction, LAVA-1207, discontinuation, mCRPC, LAVA-1266, strategic alternatives, cash runway

Pfizer Discontinues Hemophilia B Gene Therapy Beqvez, Exits Gene Therapy Field

8 months ago talkbio0Tagged Beqvez, Discontinuation (procedure), Exit, gene therapy, Hemophilia B, Pfizer, portfolio

Pfizer, Beqvez, hemophilia B, gene therapy, discontinuation, portfolio exit

Septerna Halts Phase 1 Trial of SEP-786 Due to Unexpected Bilirubin Elevations

8 months ago talkbio0Tagged Agonist, Bilirubin, Clinical Trials, Discontinuation (procedure), Hypoparathyroidism, PTH1R gene, SEP-786, Septerna

Septerna, SEP-786, clinical trial discontinuation, hypoparathyroidism, bilirubin elevation, PTH1R agonist, biotech setback

Turnstone Biologics Discontinues Final Clinical Program, Initiates Strategic Review Amid Financial Constraints

8 months ago talkbio0Tagged Arenaria, Biological Factors, clinical program, Discontinuation (procedure), Financial cost, Industry, Lymphocytes, Tumor-Infiltrating, Manufacturing, strategic alternatives, TIDAL-01

Turnstone Biologics, TIDAL-01, clinical program discontinuation, layoffs, strategic alternatives, TIL therapy, manufacturing costs, biotech industry challenges

Cargo Therapeutics Discontinues Lead CAR-T Program Due to Poor Durability and Safety Concerns

8 months ago talkbio0Tagged CAR-T therapy, cargo receptor ligand activity, Clinical Trials, Discontinuation (procedure), durability, firi-cel, Safety

CAR-T therapy, durability, safety, clinical trial discontinuation, large B-cell lymphoma, firi-cel, CARGO Therapeutics